{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:30:43Z","timestamp":1783625443864,"version":"3.55.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Copanlisib is an intravenously administered pan-class I PI3K inhibitor that has been demonstrated to have appreciable effects in the treatment of patients with lymphoma. The purpose of this meta-analysis was to evaluate the efficacy and safety of copanlisib for treating patients with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (B-NHL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PubMed, Web of Science, EMBASE, and the Cochrane Central Register of Controlled Trials were searched for relevant studies published prior to July 2022. The efficacy evaluation included complete response rate (CR), partial response rate (PR), rate of stable disease (SDR), overall response rate (ORR), disease control rate (DCR), rate of progressive disease (PDR), median progression-free survival (PFS), and median overall survival (OS). Any grade adverse events (AEs) and grade \u22653 AEs were synthesized to assess its safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eight studies with a total of 652 patients with R\/R B-NHL were identified. The pooled CR, PR, ORR, SDR, DCR, and PDR from all 8 articles were 13%, 40%, 57%, 19%, 86%, and 9%, respectively. The CR and ORR of combination therapy with rituximab were higher than those with copanlisib monotherapy for R\/R B-NHL (34% vs. 6%, p&amp;lt;0.01; 89% vs. 42%, p&amp;lt;0.01). For patients with R\/R indolent B-NHL, CR and ORR were lower with copanlisib monotherapy than with combination therapy with rituximab (7% vs. 34%, p&amp;lt;0.01; 58% vs. 92%, p&amp;lt;0.01). In R\/R B-NHL patients receiving copanlisib monotherapy and combination therapy with rituximab, the risk of any grade AEs was 99% and 96%, respectively, and the risk of grade \u22653 AEs was 84% and 91%, respectively. The common any grade AEs included hyperglycemia (66.75%), hypertension (48.57%), diarrhea (35.06%), nausea (34.98%) and fatigue (30.33%). The common grade \u22653 AEs included hyperglycemia (45.14%), hypertension (35.07%), and neutropenia (14.75%). The comparison of AEs between the copanlisib monotherapy and the combination therapy with rituximab showed that hyperglycemia of any grade (p&amp;lt;0.0001), hypertension of any grade (p=0.0368), fatigue of any grade (p&amp;lt;0.0001), grade \u22653 hypertension (p&amp;lt;0.0001) and grade \u22653 hyperglycemia (p=0.0074) were significantly different between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our meta-analysis demonstrated that the efficacy of both copanlisib monotherapy and combination therapy with rituximab in patients with R\/R B-NHL was satisfactory, while treatment-related AEs were tolerable. Compared with copanlisib monotherapy, combination therapy with rituximab showed superior efficacy for treating R\/R B-NHL, and its safety was manageable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:uri>https:\/\/inplasy.com\/inplasy-2022-10-0008\/<\/jats:uri>, identifier INPLASY2022100008.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1034253","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T04:44:15Z","timestamp":1668141855000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of copanlisib in relapsed\/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Jinjin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchun","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaolun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16489","article-title":"Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century - a Swedish lymphoma register study","volume":"189","author":"Ekberg","year":"2020","journal-title":"Br J Haematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01635.x","article-title":"Multicenter phase II study of bendamustine for relapsed or refractory indolent b-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"101","author":"Ohmachi","year":"2010","journal-title":"Cancer Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14101","article-title":"Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive b-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial","volume":"174","author":"Pettengell","year":"2016","journal-title":"Br J haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large b-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","author":"Tilly","year":"2015","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12126","article-title":"Outcomes in refractory diffuse large b-cell lymphoma: results from a multicenter real-world study in China","volume":"41","author":"Wang","year":"2021","journal-title":"Cancer Commun (London England)."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.04.025","article-title":"Non-Hodgkin lymphoma: Diagnosis and treatment","volume":"90","author":"Ansell","year":"2015","journal-title":"Mayo Clinic Proc"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000445","article-title":"Immune and cell therapy in non-Hodgkin lymphoma","volume":"26","author":"Merryman","year":"2020","journal-title":"Cancer J (Sudbury Mass)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-041863","article-title":"How I treat indolent lymphoma","volume":"109","author":"Gribben","year":"2007","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large b-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet (London England)."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1517\/14656560902895715","article-title":"Treatment strategies for relapsed and refractory aggressive non-hodgkin\u2019s lymphoma","volume":"10","author":"Prichard","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting b cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11864-020-00746-8","article-title":"PI3K inhibitors and their role as novel agents for targeted therapy in lymphoma","volume":"21","author":"Sapon-Cousineau","year":"2020","journal-title":"Curr Treat options Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cellbio.17.1.615","article-title":"Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer","volume":"17","author":"Katso","year":"2001","journal-title":"Annu Rev Cell Dev Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat Rev Genet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00540-w","article-title":"The role of PI3K inhibition in lymphoid malignancies","volume":"14","author":"von Keudell","year":"2019","journal-title":"Curr hematologic malignancy Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"20406207211006027","DOI":"10.1177\/20406207211006027","article-title":"Update on the role of copanlisib in hematologic malignancies","volume":"12","author":"Le","year":"2021","journal-title":"Ther Adv hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073464","article-title":"PI3K inhibitors in cancer: Clinical implications and adverse effects","volume":"22","author":"Mishra","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"111718","DOI":"10.1016\/j.ejmech.2019.111718","article-title":"Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer","volume":"183","author":"Elmenier","year":"2019","journal-title":"Eur J medicinal Chem"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0285-6","article-title":"Idelalisib: first global approval","volume":"74","author":"Markham","year":"2014","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1013-4","article-title":"Duvelisib: First global approval","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0195","article-title":"Copanlisib in the treatment of non-Hodgkin lymphoma","volume":"16","author":"Narkhede","year":"2020","journal-title":"Future Oncol (London England)."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0838-6","article-title":"Copanlisib: First global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25711","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study","volume":"95","author":"Dreyling","year":"2020","journal-title":"Am J hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00145-5","article-title":"Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Matasar","year":"2021","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Clinical Res ed)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J surgery."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04417-3","article-title":"A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma","volume":"89","author":"Liu","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0743-y","article-title":"Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large b-cell lymphoma","volume":"34","author":"Lenz","year":"2020","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann oncol: Off J Eur Soc Med Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-hodgkin\u2019s lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann oncol: Off J Eur Soc Med Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0466","article-title":"On-target pharmacodynamic activity of the PI3K inhibitor copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors","volume":"19","author":"Morschhauser","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.06.021","article-title":"Feasibility of combining the phosphatidylinositol 3-kinase inhibitor copanlisib with rituximab-based immunochemotherapy in patients with relapsed indolent b-cell lymphoma","volume":"21","author":"Matasar","year":"2021","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4993\/acrt.29.85","article-title":"Copanlisib in non-hodgkin\u2019s lymphoma and solid tumors: An efficacy and safety analysis","volume":"29","author":"Subedi","year":"2021","journal-title":"Ann Cancer Res Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: A phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin oncol: Off J Am Soc Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25228","article-title":"Duvelisib, an oral dual PI3K-\u03b4, \u03b3 inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study","volume":"93","author":"Flinn","year":"2018","journal-title":"Am J hematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"New Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-757740","article-title":"Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy","volume":"129","author":"Gopal","year":"2017","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0993-T","article-title":"BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models","volume":"12","author":"Liu","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway","volume":"296","author":"Cantley","year":"2002","journal-title":"Sci (New York NY)."},{"key":"B42","doi-asserted-by":"publisher","first-page":"106671","DOI":"10.1016\/j.leukres.2021.106671","article-title":"Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study","volume":"111","author":"McBride","year":"2021","journal-title":"Leukemia Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016000976","article-title":"Combinations of idelalisib with rituximab and\/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma","volume":"1","author":"de Vos","year":"2016","journal-title":"Blood advances."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25634","article-title":"Combination trial of duvelisib (IPI-145) with rituximab or bendamustine\/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia","volume":"94","author":"Flinn","year":"2019","journal-title":"Am J hematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.169656","article-title":"Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"102","author":"Younes","year":"2017","journal-title":"Haematologica"},{"key":"B46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1078-0432.CCR-16-0134","article-title":"A phase ib study of alpelisib (BYL719), a PI3K\u03b1-specific inhibitor, with letrozole in ER+\/HER2- metastatic breast cancer","volume":"23","author":"Mayer","year":"2017","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B47","article-title":"PI3K inhibitors: Understanding toxicity mechanisms and management","volume":"31","author":"Greenwell","year":"2017","journal-title":"Oncol (Williston Park NY)."},{"key":"B48","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11523-021-00802-9","article-title":"Copanlisib for the treatment of malignant lymphoma: Clinical experience and future perspectives","volume":"16","author":"Munoz","year":"2021","journal-title":"Targeted Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.11.021","article-title":"Optimal management of adverse events from copanlisib in the treatment of patients with non-Hodgkin lymphomas","volume":"19","author":"Cheson","year":"2019","journal-title":"Clin lymphoma myeloma leukemia."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S142264","article-title":"Spotlight on copanlisib and its potential in the treatment of relapsed\/refractory follicular lymphoma: evidence to date","volume":"11","author":"Mensah","year":"2018","journal-title":"OncoTargets Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1384815","article-title":"PI3K\u03b4-selective and PI3K\u03b1\/\u03b4-combinatorial inhibitors in clinical development for b-cell non-Hodgkin lymphoma","volume":"26","author":"Lampson","year":"2017","journal-title":"Expert Opin investigational Drugs"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0034","article-title":"Safety, tolerability, and management of toxic effects of phosphatidylinositol 3-kinase inhibitor treatment in patients with cancer: A review","volume":"5","author":"Esposito","year":"2019","journal-title":"JAMA Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-02929-3","article-title":"Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma","volume":"112","author":"Izutsu","year":"2020","journal-title":"Int J hematol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica"},{"key":"B56","unstructured":"COPIKTRA (duvelisib) highlights of prescribing information2018"},{"key":"B57","unstructured":"ZYDELIG (idelalisib) highlights of prescribing information2014"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1034253\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T04:44:18Z","timestamp":1668141858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1034253\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2022.1034253"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1034253","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"article-number":"1034253"}}